drugset / Trial / NCT04400487

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487

Phase 4 Completed 25 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.

Timeline

Start
2020-12-21
Primary completion
2022-09-08
Completion
2022-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Voxelotor Small molecule 1500 mg Oral

Indications